Article Title:

Variant landscape of the *RYS1* gene based on whole genome sequencing of the Singaporean population

Authors:

Claribel Tian Yu Foo^{1*}, Yi Hui To^{1*}, Astrid Irwanto, Ph.D^{2,3}, Alvin Yu-Jin Ng, Ph.D⁴, Benedict Yan, MBBS⁴, Sophia Tsong Huey Chew, MMed⁵, Jianjun Liu, Ph.D^{6,7}, Lian Kah Ti, MMed^{8,9}

*Both authors contributed equally to the study

Institutional Affiliations:

1. National University of Singapore, Yong Loo Lin School of Medicine, Singapore
2. Nalagenetics Pte. Ltd, Singapore
3. Dept of Pharmacy, Faculty of Science, National University of Singapore, Singapore
4. Molecular Diagnosis Centre, Department of Laboratory Medicine, National University Hospital, Singapore
5. Department of Anaesthesiology, Singapore General Hospital, Singapore
6. Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
7. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
8. Department of Anaesthesia, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
9. Department of Anaesthesia, National University Health System, Singapore

Corresponding Author:

Lian Kah Ti, MMed

Department of Anaesthesia, National University Health System

27 5 Lower Kent Ridge Road, Singapore 119074

28 +65 67724200

29 anatil@nus.edu.sg

30

31

32 **Acknowledgments:** We thank all the individuals who have contributed to this study.

33

34 **Word and Element Counts:** Abstract – 249 words; Introduction – 652 words; Discussion –
35 1140 words; 3 figures; 2 tables; 8 supplementary digital files.

36

37

38

39 **Abbreviations**

40 MH, malignant hyperthermia

41 SNV, single nucleotide variants

Abstract

Background

The *RYR1* gene codes for a ryanodine receptor which is a calcium release channel in the skeletal muscle sarcoplasmic reticulum. It is associated with Malignant Hyperthermia (MH) and several congenital myopathies including Central Core Disease (CCD), Multiminicore Disease (MMD) and Congenital Fibre-Type Disproportion (CFTD). There is currently little information on the epidemiology of *RYR1* variants in Asians. Our study aims to describe the *RYR1* variant landscape in a Singapore cohort unselected for *RYR1*-associated conditions.

Methods

Data was retrieved from the SG10K pilot project, where whole genome sequencing was performed on volunteers unselected and undetermined for *RYR1*-associated conditions. Variants were classified based on pathogenicity using databases ClinVar and InterVar. Allele frequencies of pathogenic variants were compared between Chinese, Indians and Malays. Using databases ExAC, GnomAD and GenomeAsia 100k study, we further compared local allele frequencies to those in Europe, America and Asia.

Results

Majority of the *RYR1* variants were missense mutations. We identified four pathogenic and four likely pathogenic *RYR1* variants. All were related to the aforementioned *RYR1*-associated conditions. There were 6 carriers of *RYR1* pathogenic variants amongst 4810 individuals, corresponding to an allele frequency of 0.06%. The prevalence of pathogenic variants was the highest amongst Indians (4 in 1127 individuals). Majority of pathogenic and likely pathogenic mutations were missense and located in mutational hotspots. These variants also occurred at higher frequencies in Asians than globally.

68 Conclusion

69 This study describes the variant landscape of the *RYS1* gene in Singapore. This knowledge will
70 facilitate local efforts in developing precision medicine.

Keywords

RYR1-associated mutations, *RYR1*-associated congenital myopathies, MH-susceptibility, variant landscape

Declarations

Funding statement:

Support was provided by the Department of Anaesthesia, National University Health System Singapore.

Conflicts of interest:

A.I. is an employee of Nalagenetics Pte Ltd. A.I. and J.L. has financial holdings in Nalagenetics Pte Ltd.

Availability of data and material: The accession number for the sequence data reported in this paper is EGA: EGAS00001003875.

Code availability: The accession number for the sequence data reported in this paper is EGA: EGAS00001003875.

Ethics approval: These studies were approved by the Institutional Review Board of the National University of Singapore (Approvals: N-17-030E and H-17-049), SingHealth Centralized Institutional Review Board (Approvals: 2006/612/A, 2014/160/A, 2018/2570, 2018/2717, 2010/196/C, 2015/2194, 2019/2046, 2009/280/D, 2014/692/D, 2002/008/A, 2002/008 g/A, 2013/605/C, 2018/3081 and 2015/2308), National Health Group Domain Specific Review Board (Approvals: 2007/00167, 2016/00269, 2018/00301, TTSH/2014-00040 and 2009/00021).

Consent to participate: This study was conducted retrospectively using data obtained from the SG10K pilot project. Written informed consent was obtained from all participants of the SG10K pilot project.

95 **Consent for publication:** This study was conducted retrospectively using data obtained from
96 the SG10K pilot project. Written informed consent was obtained from all participants of the
97 SG10K pilot project.

98

Background

The *RYR1* gene (NCBI 2020) codes for a ryanodine receptor found in the skeletal muscle and the receptor serves as a calcium release channel in the sarcoplasmic reticulum. Mutations in *RYR1* are strongly associated with Malignant Hyperthermia (MH) and congenital myopathies such as Multiminicore Disease (MMD), Central Core Disease (CCD), and Congenital Fibre-Type Disproportion (CFTD) (Todd et al. 2021).

MH is a pharmacogenetic disorder of skeletal muscle which may be inherited in an autosomal dominant fashion or arise due to *de novo* mutations in associated genes, most commonly *RYR1* (Miller et al. 2018; Rosenberg et al. 2015). MH-causative mutations in *RYR1* result in increased sensitivity of *RYR1* protein to activation (Riazi et al. 2018; Robinson et al. 2006; Treves et al. 2008). In the presence of anesthetic triggering agents, dysregulation of calcium transport results in excessive myoplasmic calcium accumulation. This manifests clinically as a hypermetabolic crisis when an MH-susceptible individual is exposed to a volatile anesthetic agent or depolarizing muscle relaxants. This syndrome is potentially lethal if left untreated. The clinical manifestations of MH include initial hypercarbia, tachypnea, generalised muscle rigidity, masseter muscle rigidity, as well as arrhythmias. Subsequently, hyperthermia and rhabdomyolysis may occur (Litman 2019).

Congenital myopathies are inherited neuromuscular disorders characterised by common histologic features seen on muscle biopsy, such as central cores, nemaline rods, multi-minicores and central nuclei. *RYR1* is associated with several such myopathies, such as CCD, certain subtypes of MMD, and CFTD. There is significant genetic, phenotypic and histopathological overlap between these myopathies, as well as considerable phenotypic variability. CCD is inherited in an autosomal dominant fashion and is characterised by hip girdle weakness with orthopaedic complications such as hip dislocation and scoliosis. MMD is

inherited in an autosomal recessive fashion and has a variety of clinical phenotypes. The most common subtype leads to spinal rigidity, scoliosis and respiratory dysfunction, and is associated with mutations in the selenoprotein N gene. Other subtypes are associated with *RYR1* mutations and can be characterised by hip girdle weakness, external ophthalmoplegia and distal muscle atrophy. Various studies have suggested that these subtypes of MMD may exist on a clinco-pathologic continuum with CCD (Jungbluth 2007; Zhou et al. 2007). CFTD can be inherited in an autosomal dominant or recessive pattern and rarely in an X-linked pattern (MedGen). It is characterised by weakness in the proximal muscle groups close to the trunk, such as the shoulder and hips. It can also result in ophthalmoplegia, ptosis (droopy eyelids) and scoliosis. *RYR1* mutations account for 10-20% of CFTD (Litman et al. 2018).

Many of the *RYR1*-associated myopathies are linked to MH-susceptibility, and it is estimated that MH-susceptibility and myopathy co-occur in at least 30% of individuals with *RYR1* pathogenic variants. As a result, patients with *RYR1*-associated myopathies should be considered MH-susceptible unless proven negative by an MH contracture biopsy (Litman et al. 2018).

Genetic testing is a common and non-invasive diagnostic test for many of these conditions. Most of the genetic studies done on *RYR1* mutations were performed on patients diagnosed with MH and other myopathies, and this is useful in identifying pathogenic variants. However, to estimate the true population prevalence of these mutations, studies need to be conducted in the general population. Our review of the existing literature revealed one such variant landscape study on the general population, however this was conducted on the American population made up of mainly Caucasians (Gonsalves et al. 2013). There is little information on the epidemiology of *RYR1* variants in the Asian population. Our study performed on the multiracial Singapore population will be useful in providing a snapshot of the spectrum of mutations in Asia.

151
152 Our study aims to describe the *RYR1* variant landscape in a Singaporean cohort unselected for
153 *RYR1*-associated myopathies and MH. We seek to define the prevalence of pathogenic variants
154 in 3 major ethnic groups in Singapore and compare it to existing databases. This will facilitate
155 genetic screening of these conditions in the Singapore population.
156

Materials and Methods

Data was retrieved from the SG10K pilot project, which is part of a national effort to eventually whole-genome sequence 10,000 Singaporeans. The aim of this study was to provide a snapshot of the genetic diversity in East Asia, Southeast Asia, and South Asia. This is possible given the ethnic diversity in Singapore, which consists mainly of Chinese (74.3%), Malays (13.4%) and Indians (9.1%). The ethnic clusters in Singapore were analysed using principal-components analysis and are further described in the SG10K pilot project. In this study, whole genome sequencing was performed on 4810 samples, including 2780 Chinese, 903 Malays and 1127 Indians. These volunteers include a mixture of healthy and diseased individuals with conditions such as heart and neurodegenerative conditions. Linkage disequilibrium (LD)-based joint calling and quality controls were performed to remove low-quality variants and population-based phasing to obtain haplotypes. After removing relatedness up to the third degree, a subset of 4,441 unrelated individuals were obtained. Further details on the methodology can be obtained from the SG10K paper (Wu et al. 2019).

ClinVar and InterVar were used to classify variants into “benign”, “likely benign”, “uncertain significance”, “likely pathogenic” and “pathogenic”. ClinVar is a database of clinical variations which collects data on genotype-phenotype relationships from various contributors. It aggregates the submissions and reports the clinical significance of variants based on the American College of Medical Genetics (ACMG) and Association for Molecular Pathology (AMP) Guidelines (NCBI). InterVar is a bioinformatics software which classifies variants via automation of the 2015 ACMG/AMP guidelines (Li and Wang). ClinVar serves as our main reference for determining the clinical significance of variants as the classifications are more thoroughly supported with published evidence. The variant positions for RYR1 refer to NM_001042723.

182 Variants were also classified based on the location and type of mutations. Single Nucleotide
183 Variant (SNV) types include synonymous SNV, missense SNV, stop gain SNV, stop loss SNV
184 and unknown. Indel variant types include frameshift insertion, frameshift deletion, stop gain,
185 stop loss, non-frameshift insertion, non-frameshift deletion and unknown.

186
187 Allele frequencies were compared between the Chinese, Indian and Malay population in
188 Singapore. Allele frequencies in the Singapore population were also compared against
189 European, American and Asian populations using databases ExAC (Exome Aggregation
190 Consortium) (ExAC), GnomAD (Genome Aggregation Database) (gnomAD), and data from the
191 GenomeAsia 100k study (GenomeAsia).

192
193 These studies were approved by the Institutional Review Board of the National University of
194 Singapore (Approvals: N-17-030E and H-17-049), SingHealth Centralized Institutional Review
195 Board (Approvals: 2006/612/A, 2014/160/A, 2018/2570, 2018/2717, 2010/196/C, 2015/2194,
196 2019/2046, 2009/280/D, 2014/692/D, 2002/008/A, 2002/008 g/A, 2013/605/C, 2018/3081 and
197 2015/2308), National Health Group Domain Specific Review Board (Approvals: 2007/00167,
198 2016/00269, 2018/00301, TTSH/2014-00040 and 2009/00021).

199
200 Statistical analysis was not performed as the number of variants is small and significance
201 testing is not meaningful.

202

Results

Types of mutations found

All the *RYR1* variants were classified based on mutation type (Figure 1). All of these mutations occurred in exonic regions. Majority of the mutations were missense, followed by synonymous variants.

Classification of *RYR1* variants based on clinical significance

The *RYR1* variants found in our study were classified based on their clinical significance given by ClinVar (online resource table S1) and InterVar (online resource table S2). ClinVar was used as the main reference for defining the clinical significance of the variants. Based on ClinVar, there were 4 pathogenic and 2 likely pathogenic variants for *RYR1*. Based on InterVar, there were 1 pathogenic and 6 likely pathogenic *RYR1* variants. Of these, all overlapped with the pathogenic and likely pathogenic variants found in ClinVar except for 2 likely pathogenic variants. Table 1 summarizes the list of pathogenic and likely pathogenic *RYR1* variants found in our study. Table 2 and online resource table S3 provide details on the specific diseases associated with each variant. The majority of pathogenic and likely pathogenic *RYR1* variants in our study were missense mutations, except for 2 nonsense mutations (Table 1).

In terms of the location of pathogenic and likely pathogenic *RYR1* mutations, all but 2 likely pathogenic variants were found in mutational hotspots. These *RYR1* mutational hotspots have been previously identified to include the N-terminal region between codons 34 and 614 (exons 2 to 19), central region between codons 2163 and 2458 (exons 39 to 47), and C-terminal region between codons 4136 and 4973 (exons 85 to 104) (Gillies et al. 2008). There was no clear pattern as to the exons in which the pathogenic and likely pathogenic mutations were found. However, we found that most of the pathogenic and likely pathogenic *RYR1* variants have mutations occurring in highly conserved regions (online resource table S4).

230 Table 1: Pathogenic and likely pathogenic *RYR1* variants in the Singapore population

Variant	ClinVar classification	InterVar classification	Number of carriers	Ethnicity of carriers	Exon number	Type of mutation
c.325C>T (p.Arg109Trp)	Pathogenic	Likely pathogenic	1	Chinese	4/106	Missense
c.6487C>T (p.Arg2163Cys)	Pathogenic	Likely pathogenic	1	Malay	39/106	Missense
c.7268T>A (p.Met2423Lys)	Pathogenic	Variant of uncertain significance	3	Indian	45/106	Missense
c.14111C>T (p.Thr4704Met)	Pathogenic	Likely pathogenic	1	Indian	96/106	Missense
c.742G>T (p.Gly248Trp)	Likely pathogenic	Likely pathogenic	1	Chinese	12/106	Missense
c.1186G>T (p.Glu396X)	NA*	Pathogenic	3	Malay	9/106	Stop gained
c.2654G>A (p.Arg885His)	Conflicting**	Likely pathogenic	3	Indian	21/106 (outside mutational hotspot)	Missense
c.8554C>T (p.Arg2852X)	Variant of uncertain significance	Likely pathogenic	1	Chinese	55/106 (outside mutational hotspot)	Stop gained

231 Both ClinVar and InterVar classifications are included in this table. (Orange: defined as pathogenic in this
232 study; Blue: defined as likely pathogenic in this study)

233 *Not found in ClinVar

234 **Conflicting refers to when different submitters assign different clinical significance to a variant. This
235 includes variants which have the following combination of classifications from different submitters:

- 236 1. (Pathogenic or Likely pathogenic or Benign or Likely benign) AND Uncertain significance
237 2. (Pathogenic or Likely pathogenic) AND (Benign or Likely benign)

238

239 Table 2: Diseases associated with pathogenic and likely pathogenic *RYR1* variants

Variant	Malignant hyperthermia susceptibility	Minicore myopathy with external ophthalmoplegia	Congenital myopathy with fibre type disproportion	Central core myopathy
---------	---------------------------------------	---	---	-----------------------

c.325C>T (p.Arg109Trp)	-	Pathogenic	Likely pathogenic	-
c.6487C>T (p.Arg2163Cys)	Pathogenic	-	-	Pathogenic
c.7268T>A (p.Met2423Lys)	-	Pathogenic	Pathogenic	-
c.14111C>T (p.Thr4704Met)	Likely pathogenic/ Variant of uncertain significance**	Pathogenic	Likely pathogenic	Pathogenic
c.742G>T (p.Gly248Trp)	Likely pathogenic	-	-	-
c.1186G>T (p.Glu396X)*	-	-	-	-
c.2654G>A (p.Arg885His)	Variant of uncertain significance	Variant of uncertain significance	Variant of uncertain significance	-
c.8554C>T (p.Arg2852X)***	-	-	-	-

*Not found in ClinVar. Labelled as pathogenic in InterVar.

**Various submitters to ClinVar provided different clinical significance for this variant in relation to MH-susceptibility.

***Labelled as Variant of uncertain significance for RYR1-related disorders in ClinVar. Disorders were not specified.

“-”: No information regarding the clinical significance of the RYR1 variant in relation to this disease

Ethnic distribution of the carriers of the pathogenic *RYR1* variants

The ethnic distribution of pathogenic *RYR1* variants was analysed. Indians made up the majority (67%) of the individuals who carried pathogenic variants (online resource figure S1).

On further analysis of the ethnic distribution, each *RYR1* variant was found exclusively in a single ethnicity. Of the 4 pathogenic variants identified by ClinVar, 1 was present in Chinese, 2

in Indians, and 1 in a Malay. All variants were present at similar frequencies (only 1 carrier), except c.7268T>A which was present in 3 Indian carriers (Figure 2).

The analysis was repeated with both pathogenic and likely pathogenic *RYR1* variants. Indians still made up the largest proportion of carriers (50%) (online resource figure S2). Further analysis similarly revealed that each *RYR1* variant was unique to each ethnicity. Of the 8 pathogenic and likely pathogenic variants, 3 were present in the Chinese, 2 were present in the Malays and 3 in the Indians. Three of the variants occurred at higher frequencies – c.7268T>A was found in 3 Indians as previously mentioned, c.1186G>T was found in 3 Malays and c.2654G>A in 3 Indians (online resource figure S3).

Allele frequencies across different populations

Allele frequencies of 2 of the pathogenic *RYR1* variants (c.7268T>A and c.14111C>T) found in our study were higher in Singapore than globally (online resource table S5). c.325C>T occurred at higher frequencies in the Non-Finnish European population based on the ExAC database. c.6487C>T occurred at higher frequencies in the South Asian population based on the gnomAD database. Amongst the likely pathogenic variants, 3 variants (c.1186G>T, c.2654G>A and c.8554C>T) occurred at higher allele frequencies in Singapore than globally. Only variant c.742G>T had a higher allele frequency in the South Asian population based on the GenomeAsia 100K study.

In sum, allele frequencies of the pathogenic and likely pathogenic variants found in our study were generally higher amongst Asians (Singapore population and South Asian population) than globally. Comparing between the Singapore population and South Asian population, different databases have provided different allele frequencies for the South Asian population and

279 therefore we are unable to conclude if these variants occur at higher frequencies in either
280 population. Data from other parts of Asia is also lacking.

Discussion

Most of the genetic studies on *RYR1* have been conducted on populations selected for *RYR1*-associated disorders, and there is limited information on the epidemiology of *RYR1* variants in the Asian population. This is the first paper that analyses the genetic landscape of *RYR1* specifically in the Singapore population.

The prevalence of pathogenic *RYR1* variants in our study was 6 in 9620, corresponding to an estimate of 1 in 2000 in the Singapore population. Interestingly, we found that the prevalence of pathogenic *RYR1* variants in Indians was 4 in 1127, much higher than in Chinese and Malays (1 in 2780 and 1 in 903 respectively). The allele frequencies of the pathogenic variants found in our study were generally higher in Asians (Singapore population and South Asian population) than globally. In terms of the location of *RYR1* mutations, those found in our study largely occurred within established mutational hotspots.

Significance of the pathogenic variants found

The pathogenic *RYR1* variants found were closely associated with diseases such as MH, MMD, CCD and CFTD.

RYR1 gene encodes the Ca^{2+} -dependent, Ca^{2+} channel ryanodine receptor 1 (*RYR1*) found on the sarcoplasmic reticulum of the skeletal muscle (Beam et al. 2016).

MH occurs due to dysregulation of Ca^{2+} transport caused by abnormal functioning of the skeletal muscle excitation-contraction (EC) coupling complex which comprises of an L-type voltage-gated Ca^{2+} channel (dihydropyridine receptor, DHPR) and a Ca^{2+} -dependent, Ca^{2+} channel (*RYR1*). Excessive Ca^{2+} release from the sarcoplasmic reticulum causes uncontrolled muscle contraction (Santulli et al. 2018).

Mutations in the *RYR1* gene are also a common cause of congenital myopathies. Dominant mutations have been associated with CCD, while recessive mutations are associated with MMD and CFTD. Mutations associated with CCD leads to chronic channel dysfunction either through excitation-contraction uncoupling or persistent channel leakiness. However, little is known about recessive mutations and their mechanism of illness (Amburgey et al. 2013).

Four pathogenic *RYR1* variants were found and depicted in Figure 3. The N-terminal domains (NTD) make key interactions with other domains to stabilise the cytosolic assembly, and these interactions have also been implicated in channel gating and pore opening. c.325C>T is located in NTD-A, and both c.6487C>T and c.7268T>A are located in the helical domain (B-Sol). Both NTD-A and B-Sol are involved in key interprotomer contacts (Wang et al. 2005). In the context of MH, mutations at these points of contact may weaken the interfaces and facilitate pore opening and spurious Ca²⁺ leak (Santulli et al. 2018). c.6487C>T is a known causative mutation for MH and the amino acid substitution alters the conformational state of *RYR1*, exposing the receptor's activating sites to stimulatory agents (Treves et al. 2005). c.325C>T and c.7268T>A occur due to mutations affecting highly conserved amino acid residues and are known to be autosomal recessive in relation to *RYR1*-related myopathies (Zhiguang Yuchi 2013; Zhou et al. 2007). However, they have yet to be studied in relation to the MH-susceptibility phenotype.

c.14111C>T affects a highly conserved amino acid residue (Zhou et al. 2007) located within the transmembrane helices S2-S3. It is hypothesised that this region participates in calcium-sensing and calcium-dependent inactivation of *RYR* (Zalk et al. 2015). This mutation is known to be autosomal recessive in relation to *RYR1*-related myopathies (Zhou et al. 2007). There is conflicting evidence for the clinical significance of this *RYR1* variant in relation to MH, with some suggesting that it is likely pathogenic for MH and others suggesting that it is a variant of

unknown significance (NCBI 2019). Further studies are needed to definitively conclude its relation to MH-susceptibility.

Limitations

This study is a retrospective study done using anonymised genetic data from the SG10K study. We therefore lacked access to the medical histories of the study participants. Hence, we are unable to determine if the carriers of these pathogenic *RYR1* variants displayed phenotypes of the associated diseases, and we also cannot determine the penetrance of these mutations.

As we have mentioned, our study population contains a mixture of healthy and diseased individuals with comorbidities such as eye, neurodegenerative, metabolic, cardiac diseases. However, *RYR1* is not found to be associated with these diseases. Hence the enrichment of mutations within *RYR1* should not be related to the presence of such co-morbidities within the sample population.

Application

According to the EMHG guidelines, evaluation of patients for MH-susceptibility involves assessing for risk factors such as family history of MH or unexplained perioperative death, personal adverse reaction to general anaesthesia, postoperative or exertional rhabdomyolysis or exertional heat stroke. For patients with such risk factors, further testing is recommended. The decision between IVCT and genetic testing depends on several factors: the availability of the respective test, the urgency of test, the prior probability of a positive diagnosis and the cost of the tests. Genetic testing offers a less invasive option but is less sensitive than IVCT. Patients with a negative genetic screening result may proceed to do an IVCT to conclusively exclude MH susceptibility. Genetic testing has a major role in family screening and its cost-effectiveness makes it a viable option as the primary investigation of index cases (Girard 2015). The North

American MH Genetic Group also adopts a similar approach by incorporating genetic testing into its screening protocol (Nelson et al. 2004). Disclosure of incidental findings from MH-susceptibility genetic screening in generally healthy individuals has also been found to reduce cost by USD \$900 and increase quality-adjusted life years (QALYs) by 0.09 (Bennette et al. 2015).

Currently there is no active screening for MH-susceptibility in Singapore due to the fact that MH is a rare condition and that genetic testing is still relatively costly to the individual. Screening for malignant hyperthermia is only done through history-taking. Genetic testing will only be offered for individuals with clinical suspicion of MH-susceptibility. Currently, muscle contracture test is not available in Singapore. However, as Singapore moves towards precision medicine with initiatives such as the National Precision Medicine Initiative, the findings in our study will be valuable in helping to expanding our knowledge of the variant landscape of various genes in Singapore. This will facilitate subsequent efforts to provide cost effective genetic testing and personalised medicine to patients in the future.

Since there is significant overlap between MH susceptibility and congenital myopathies, we recommend genetic screening for malignant hyperthermia in patients with congenital myopathies and vice versa (Litman et al. 2018).

Conclusion

From this study, we conclude that the prevalence of the pathogenic *RYR1* variants found in our study is higher amongst Asians than globally. Indians made up the majority of the individuals who carried pathogenic variants, compared to Chinese and Malays. The pathogenic variants were associated with diseases such as MH, MMD, CCD and CFTD. This paper also confirms that the variants found in our population are indeed rare and unique to individuals, suggesting a

385 need to conduct genetic screening using sequencing rather than methods which look at specific
386 mutations known to the database.

Figures and figure legends

388

389 **Fig. 1** Mutation counts and types for *RYR1* variants in SG10K pilot data

Fig. 2 Ethnic distribution of individual pathogenic *RYR1* variants

Fig. 3 Schematic diagram of *RYR1* protein subunit and pathogenic variants in this study

RYR1 is a homotetramer with each subunit consisting of a large cytoplasmic moiety and a transmembrane domain. This figure depicts one subunit of the *RYR1* protein. The cytoplasmic moiety contains (1) the N-terminal domain (NTD) with 3 subdomains (A, B, C), (2) 3 SPRY domains (SPRY 1, 2, 3), of which SPRY 2 and 3 interact with the $\alpha 1$ subunit of DHPR at the II-III loop region, (3) a solenoid region comprising the handle/ junctional solenoid (J-sol) domain, and the helical (HD1, HD2)/ bridging solenoid (B-Sol) domains, (4) 2 tandem repeat domains (R1&2, R3&4), and (5) a Central domain or core

400 solenoid (C-Sol). The transmembrane domain consists of 6 transmembrane helices (S1-6), and a C-
401 terminal domain (CTD). S5 and 6, together with a pore helix in between S5 and S6, make up the pore-
402 forming region (PF) [19, 25, 36]. The amino acid residue numbers for the various domains have been
403 labelled, and the pathogenic *RYP1* mutations are indicated at their various positions across the protein

References

- Amburgey K, Bailey A, Hwang JH, Tarnopolsky MA, Bonnemann CG, Medne L, Mathews KD, Collins J, Daube JR, Wellman GP, Callaghan B, Clarke NF, Dowling JJ (2013) Genotype-phenotype correlations in recessive RYR1-related myopathies. *Orphanet Journal of Rare Diseases* 8: 117. doi: 10.1186/1750-1172-8-117
- Beam TA, Loudermilk EF, Kisor DF (2016) Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia. *Physiological Genomics* 49: 81-87. doi: 10.1152/physiolgenomics.00126.2016
- Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL (2015) The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. *Genet Med* 17: 587-95. doi: 10.1038/gim.2014.156
- ExAC ExAC browser. <http://exac.broadinstitute.org/>.
- GenomeAsia GenomeAsia 100k. <https://genomeasia100k.org/>. Accessed 2020
- Gillies RL, Bjorksten AR, Davis M, Du Sart D (2008) Identification of genetic mutations in Australian malignant hyperthermia families using sequencing of RYR1 hotspots. *Anaesth Intensive Care* 36: 391-403. doi: 10.1177/0310057x0803600311
- Girard T (2015) Testing for MH susceptibility. <https://www.emhq.org/testing-for-mh>.
- gnomAD gnomAD. <https://gnomad.broadinstitute.org/>.
- Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, Mullikin JC, Biesecker LG, Program NCS (2013) Using exome data to identify malignant hyperthermia susceptibility mutations. *Anesthesiology* 119: 1043-1053. doi: 10.1097/ALN.0b013e3182a8a8e7
- Jungbluth H (2007) Multi-minicore Disease. *Orphanet journal of rare diseases* 2: 31-31. doi: 10.1186/1750-1172-2-31
- Li Q, Wang K InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines. *Am J Hum Genet* 100: 267-280. doi: 10.1016/j.ajhg.2017.01.004
- Litman RS (2019) Malignant hyperthermia: Diagnosis and management of acute crisis. In: Jones SB (ed) *UpToDate*. UpToDate
- Litman RS, Griggs SM, Dowling JJ, Riazi S (2018) Malignant Hyperthermia Susceptibility and Related Diseases. *Anesthesiology* 128: 159-167. doi: 10.1097/ALN.0000000000001877
- MedGen Congenital myopathy with fiber type disproportion. NCBI
- Miller DM, Daly C, Aboelsaod EM, Gardner L, Hobson SJ, Riasat K, Shepherd S, Robinson RL, Bilmen JG, Gupta PK, Shaw MA, Hopkins PM (2018) Genetic epidemiology of malignant hyperthermia in the UK. *British Journal of Anaesthesia* 121: 944-952. doi: <https://doi.org/10.1016/j.bja.2018.06.028>
- NCBI ClinVar and ClinGen. <https://www.ncbi.nlm.nih.gov/clinvar/docs/clingen/>.
- NCBI (2019) NM_000540.2(RYR1):c.14126C>T (p.Thr4709Met). 27 Nov 2019 edn. NCBI
- NCBI (2020) RYR1 ryanodine receptor 1 [Homo sapiens (human)]. NCBI.
- Nelson Thomas E, Ph.D., Rosenberg H, M.D., Muldoon Sheila M, M.D. (2004) Genetic Testing for Malignant Hyperthermia in North America. *Anesthesiology: The Journal of the American Society of Anesthesiologists* 100: 212-214.
- Riazi S, Kraeva N, Hopkins PM (2018) Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. *Anesthesiology* 128: 168-180. doi: 10.1097/ALN.0000000000001878
- Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. *Hum Mutat* 27: 977-89. doi: 10.1002/humu.20356
- Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K (2015) Malignant hyperthermia: a review. *Orphanet Journal of Rare Diseases* 10: 93. doi: 10.1186/s13023-015-0310-1

- 454 Santulli G, Lewis D, des Georges A, Marks AR, Frank J (2018) Ryanodine Receptor Structure
455 and Function in Health and Disease. *Sub-cellular biochemistry* 87: 329-352. doi:
456 10.1007/978-981-10-7757-9_11
- 457 Todd JJ, Goldberg MF, Dirksen RT, Voermans NC (2021) RYR1-related diseases.
458 <https://rarediseases.org/rare-diseases/ryr-1-related-diseases/>.
- 459 Treves S, Anderson AA, Ducreux S, Divet A, Bleunven C, Grasso C, Paesante S, Zorzato F
460 (2005) Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and
461 neuromuscular disorders. *Neuromuscul Disord* 15: 577-87. doi:
462 10.1016/j.nmd.2005.06.008
- 463 Treves S, Jungbluth H, Muntoni F, Zorzato F (2008) Congenital muscle disorders with cores: the
464 ryanodine receptor calcium channel paradigm. *Curr Opin Pharmacol* 8: 319-26. doi:
465 10.1016/j.coph.2008.01.005
- 466 Wang Q, Liu M, Xu C, Tang Z, Liao Y, Du R, Li W, Wu X, Wang X, Liu P, Zhang X, Zhu J, Ren
467 X, Ke T, Wang Q, Yang J (2005) Novel CACNA1S mutation causes autosomal dominant
468 hypokalemic periodic paralysis in a Chinese family. *Journal of molecular medicine*
469 (Berlin, Germany) 83: 203-208. doi: 10.1007/s00109-005-0638-4
- 470 Wu D, Dou J, Chai X, Bellis C, Wilm A, Shih CC, Soon WWJ, Bertin N, Lin CB, Khor CC,
471 DeGiorgio M, Cheng S, Bao L, Karnani N, Hwang WYK, Davila S, Tan P, Shabbir A,
472 Moh A, Tan E-K, Foo JN, Goh LL, Leong KP, Foo RSY, Lam CSP, Richards AM, Cheng
473 C-Y, Aung T, Wong TY, Ng HH, Ackers-Johnson MA, Aliwarga E, Ban KHK, Bertrand D,
474 Chambers JC, Chan DLH, Chan CXL, Chee ML, Chee ML, Chen P, Chen Y, Chew
475 EGY, Chew WJ, Chiam LHY, Chong JPC, Chua I, Cook SA, Dai W, Dorajoo R, Foo C-S,
476 Goh RSM, Hillmer AM, Irwan ID, Jaufeerally F, Javed A, Jeyakani J, Koh JTH, Koh JY,
477 Krishnaswamy P, Kuan JL, Kumari N, Lee AS, Lee SE, Lee S, Lee YL, Leong ST, Li Z,
478 Li PY, Liew JX, Liew OW, Lim SC, Lim WK, Lim CW, Lim TB, Lim CK, Loh SY, Lok AW,
479 Chin CWL, Majithia S, Maurer-Stroh S, Meah WY, Mok SQ, Nargarajan N, Ng P, Ng SB,
480 Ng Z, Ng JYX, Ng E, Ng SL, Nusinovici S, Ong CT, Pan B, Pedergnana V, Poh S,
481 Prabhakar S, Prakash KM, Quek I, Sabanayagam C, See WQ, Sia YY, et al. (2019)
482 Large-Scale Whole-Genome Sequencing of Three Diverse Asian Populations in
483 Singapore. *Cell* 179: 736-749.e15. doi: 10.1016/j.cell.2019.09.019
- 484 Zalk R, Clarke OB, des Georges A, Grassucci RA, Reiken S, Mancina F, Hendrickson WA, Frank
485 J, Marks AR (2015) Structure of a mammalian ryanodine receptor. *Nature* 517: 44-9. doi:
486 10.1038/nature13950
- 487 Zhiguang Yuchi LKaFVP (2013) Structural Insights Into Disease Mutations of the Ryanodine
488 Receptor
- 489 Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H, Rose MR,
490 Brockington M, Kinali M, Manzur A, Robb S, Appleton R, Messina S, D'Amico A,
491 Quinlivan R, Swash M, Müller CR, Brown S, Treves S, Muntoni F (2007) Molecular
492 mechanisms and phenotypic variation in RYR1-related congenital myopathies. *Brain*
493 130: 2024-36. doi: 10.1093/brain/awm096
- 494

495 **List of supplemental material**

496 Online resource figure S1: Ethnic distribution of all pathogenic *RYR1* variants

497 Online resource figure S2: Ethnic distribution of all pathogenic and likely pathogenic *RYR1*

498 variants

499 Online resource figure S3: Ethnic distribution of individual pathogenic and likely pathogenic

500 *RYR1* variants

501 Online resource table S1: Clinical significance of *RYR1* and *CACNA1S* variants based on

502 ClinVar

503 Online resource table S2: Clinical significance of *RYR1* and *CACNA1S* variants based on

504 InterVar

505 Online resource table S3: Diseases associated with pathogenic and likely pathogenic *RYR1*

506 variants with supporting evidence from ClinVar

507 Online resource table S4: Conservation of mutation sites. Evidence was obtained from Clinvar

508 Online resource table S5: Allele frequencies of the pathogenic and likely pathogenic *RYR1*

509 variants

Online resource figure S1: Ethnic distribution of all pathogenic *RYR1* variants

Online resource figure S2: Ethnic distribution of all pathogenic and likely pathogenic *RYR1* variants

519 Online resource figure S3: Ethnic distribution of individual pathogenic and likely pathogenic

520 *RYR1* variants

521

522

523 Online resource table S1: Clinical significance of *RYR1* variants based on ClinVar.

Clinvar classification	Number (percentage) of <i>RYR1</i> variants
Pathogenic	4 (0.7%)
Likely Pathogenic	2 (0.3%)
Variant of uncertain significance	88 (15.6%)
Likely benign	0 (0.0%)
Benign	0 (0.0%)
Conflicting*	33 (5.9%)
Unclassified	437 (77.5%)

524 *Conflicting refers to when different submitters assign different clinical significance to a variant. This

525 includes variants which have the following combination of classifications from different submitters:

526 1. (Pathogenic or Likely pathogenic or Benign or Likely benign) AND Uncertain significance

527 2. (Pathogenic or Likely pathogenic) AND (Benign or Likely benign)

528

529

530

531 Online resource table S2: Clinical significance of *RYR1* variants based on InterVar.

InterVar classification	Number (percentage) of <i>RYR1</i> variants
Pathogenic	1 (0.2%)
Likely Pathogenic	6 (1.1%)
Variant of uncertain significance	274 (48.5%)
Likely benign	237 (42.0%)
Benign	28 (5.0%)
Unclassified	18 (3.2%)

532

533 Online resource table S3: Diseases associated with pathogenic and likely pathogenic *RYR1*

534 variants with supporting evidence from ClinVar

Variant	Interpreted conditions	ClinVar interpretation	Evidence
c.325C>T (p.Arg109Trp)	Minicore myopathy with external ophthalmoplegia	Pathogenic	Mutation found in 2 minicore myopathy patients from 1 family with disease onset in the neonatal period (https://pubmed.ncbi.nlm.nih.gov/16380615/)
	Congenital myopathy with fibre type disproportion	Likely pathogenic	The following ACMG criteria were applied in classifying this variant: PS1, PM2, PP3*.
c.6487C>T (p.Arg2163Cys)	1. Malignant hyperthermia susceptibility 2. Central core myopathy	Pathogenic	1. Mutation found in individuals from 2 families who had malignant hyperthermia episodes (https://www.cell.com/ajhg/fulltext/S0002-9297(07)63840-3); annotated in PharmGKB database as associated with Malignant Hyperthermia (Level 1A evidence) (https://www.pharmgkb.org/clinicalAnnotation/1183705797) 2. Submitted from GeneReviews, converted during submission to pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/submitters/500062/)
c.7268T>A (p.Met2423Lys)	1. Minicore myopathy with	Pathogenic	1. Mutation found in 4 individuals from 1 family with disease onset in infancy and childhood (https://

	external ophthalmoplegia 2. Congenital myopathy with fibre type disproportion 3. Clubfoot 4. EMG abnormality 5. Lower limb amyotrophy		pubmed.ncbi.nlm.nih.gov/16380615/ 2-5. Submitted by Centre for Mendelian Genomics, University Medical Centre Ljubljana (https://www.ncbi.nlm.nih.gov/clinvar/submitters/505952/)
c.14111C>T (p.Thr4704Met)	1. Minicore myopathy with external ophthalmoplegia 2. Central core myopathy	Pathogenic	1. Mutation associated with clinical features of the disease and molecular studies showed an association with lower levels of RYR1 protein on western blot analysis (https://pubmed.ncbi.nlm.nih.gov/17483490/) 2. Submitted from GeneReviews (https://www.ncbi.nlm.nih.gov/clinvar/variation/65996/evidence/)
	1. Central core myopathy 2. Congenital myopathy with fiber type disproportion 3. Malignant hyperthermia susceptibility 4. Minicore myopathy with external ophthalmoplegia	Likely pathogenic	Submitted from Fulgent Genetics (https://www.ncbi.nlm.nih.gov/clinvar/variation/65996/evidence/)
	Malignant hyperthermia susceptibility	Variant of uncertain significance	This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this

			variant is classified as a variant of unknown significance. (https://www.ncbi.nlm.nih.gov/clinvar/variation/65996/evidence/)
c.742G>T (p.Gly248Trp)	Malignant hyperthermia	Likely pathogenic	Segregated with malignant hyperthermia in 1 out of 45 families tested (https://www.sciencedirect.com/science/article/abs/pii/S088875439290042Q)
c.1186G>T (p.Glu396X)**	NA	NA	NA
c.2654G>A (p.Arg885His)	1. Malignant hyperthermia susceptibility 2. Minicore myopathy with external ophthalmoplegia 3. Congenital myopathy with fiber type disproportion	Uncertain significance	1. This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. (https://www.ncbi.nlm.nih.gov/clinvar/variation/212100/evidence/)

			2, 3. Submitted from Genomic Research Center, Shahid Beheshti University of Medical Services and Illumina Clinical Services Laboratory
c.8554C>T (p.Arg2852X)	RYR1-related disorders	Variant of uncertain significance	<p>The RYR1 c.8554C>T (p.Arg2852Ter) stop-gained variant has been reported in one study in which it was found in a compound heterozygous state in one individual with muscular dystrophy and arthrogryposis (Vasli et al. 2012). The individual's affected twin brother was a compound heterozygote for the same two variants, but it is not known whether the twin brothers were monozygotic or dizygotic. The p.Arg2852Ter variant was also found in a heterozygous state in an unaffected sibling and an unaffected parent. Control data are unavailable for this variant, and the variant is not found in the 1000 Genomes Project, the Exome Sequencing Project, or the Exome Aggregation Consortium. The disease description in this family is most consistent with multiminicore disease, but there is considerable overlap of disease symptoms with central core disease and congenital neuromuscular disease with uniform type 1 fiber. The p.Arg2852Ter variant has not been reported in the literature in association with malignant hyperthermia susceptibility. Due to the potential impact of stop-gained variants and the evidence from the literature, the p.Arg2852Ter variant is classified as a variant of unknown</p>

			significance but suspicious for pathogenicity for RYR1-related disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. (https://www.ncbi.nlm.nih.gov/clinvar/variation/329081/evidence/)
--	--	--	---

535 *PS1: same amino acid change known; PM2: absent from controls; PP3: in silico evidence

536 **Not found in ClinVar. Labelled as pathogenic in InterVar.

537

538 Online resource table S4: Conservation of mutation sites. Evidence was obtained from Clinvar.

539

Variant	Clinical significance	Evidence
c.325C>T (p.Arg109Trp)	Pathogenic	This sequence change replaces arginine with tryptophan at codon 109 of the <i>RYR1</i> protein (p.Arg109Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan.
c.6487C>T (p.Arg2163Cys)	Pathogenic	The R2163C variant is a non-conservative amino acid substitution, which occurs at a position that is conserved across species.
c.7268T>A (p.Met2423Lys)	Pathogenic	In 3 sibs with minicore myopathy with external ophthalmoplegia (255320) originally reported by Swash and Schwartz (1981), Jungbluth et al. (2005) identified a 7268T-A transversion in exon 45 the <i>RYR1</i> gene, resulting in a met2423-to-lys substitution in a highly conserved region.
c.14111C>T (p.Thr4704Met)	Pathogenic	This sequence change replaces threonine with methionine at codon 4709 of the <i>RYR1</i> protein (p.Thr4709Met). The threonine residue is highly conserved and there is a moderate physicochemical difference between threonine and methionine.
c.742G>T (p.Gly248Trp)	Likely pathogenic	No evidence about the conservation of the mutation site.
c.1186G>T (p.Glu396X)	Likely pathogenic	No evidence about the conservation of the mutation site.

c.2654G>A (p.Arg885His)	Likely pathogenic	This sequence change replaces arginine with histidine at codon 885 of the <i>RYS1</i> protein (p.Arg885His). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and histidine.
c.8554C>T (p.Arg2852X)	Likely pathogenic	No evidence about the conservation of the mutation site.

541 Online resource table S5: Allele frequencies of the pathogenic and likely pathogenic *RYR1* variants

Variant	AF_AF (%)	CHS_AF (%)	INS_AF (%)	MAS_AF (%)	ExAC_AF (%)	GnomAD_exome_ALL (%)	AMR_AF (%)	NFE_AF (%)	SAS_AF (%)	SEA_AF (%)	NEA_AF (%)
c.325C>T	0.01	0.018	0	0	0.01	0.008	0.009 (ExAC) 0.003 (gnomAD)	0.02 (ExAC) 0 (gnomAD)	0.006 (ExAC) 0 (gnomAD)	Nil	Nil
c.6487C>T	0.01	0	0	0.055	Nil	0.001	0.003 (gnomAD)	0 (gnomAD)	0.02 (gnomAD)	Nil	Nil
c.7268T>A	0.03	0	0.133	0	0.004	0.002	0 (ExAC) 0.02 (gnomAD)	0 (ExAC and gnomAD)	0.03 (ExAC) 0 (gnomAD)	Nil	Nil
c.14111C>T	0.01	0	0.044	0	0.002	0.004	0 (ExAC) 0.003 (gnomAD)	0.003 (ExAC) 0 (gnomAD)	0 (ExAC and gnomAD)	Nil	Nil
c.742G>T	0.01	0.018	0	0	0.001	0.001	0 (ExAC and gnomAD)	0 (ExAC and gnomAD)	0 (ExAC and gnomAD) 0.069 (genome asia 100k)	0 (genome asia 100K)	0 (genome asia 100k)
c.1186G>T	0.03	0	0	0.166	0.001	0.001	0 (ExAC and gnomAD)	0.002 (ExAC)	0 (ExAC and gnomAD)	Nil	Nil

								0 (gnomAD)			
c.2654G>A	0.031	0	0.133	0	0.02	0.02	0 (ExAC) 0.04 (gnomAD)	0.02 (ExAC) 0 (gnomAD)	0.04 (ExAC) 0 (gnomAD)	Nil	Nil
c.8554C>T	0.01	0.018	0	0	Nil	0	0 (gnomAD)	0 (gnomAD)	0 (gnomAD)	Nil	Nil

542 Orange: defined as pathogenic in this study; Blue: defined as likely pathogenic in this study.

543 Abbreviations: All_AF: allele frequency in the Singapore population; CHS_AF: allele frequency amongst Chinese; INS: allele frequency amongst
544 Indians; MAS: allele frequency amongst Malays; ExAC_ALL: allele frequency in the ExAC browser; GnomAD_exome ALL: allele frequency in the
545 gnomAD browser; AMR_AF: allele frequency in the American population; NFE_AF: allele frequency in the Non-Finnish European population;
546 SAS_AF: allele frequency in the South Asian population; SEA_AF: allele frequency in the Southeast Asian population; NEA_AF: allele frequency
547 in the Northeast Asian population. Nil: no data available

■ Frameshift variant

■ Inframe insertion

■ Missense variant, splice region variant

■ Stop gained

■ Inframe deletion

■ Missense variant

■ Splice region variant, synonymous variant

■ Synonymous variant

Cytoplasmic moiety

Table 1: Pathogenic and likely pathogenic *RYR1* variants in the Singapore population

Variant	ClinVar classification	InterVar classification	Number of carriers	Ethnicity of carriers	Exon number	Type of mutation
c.325C>T (p.Arg109Trp)	Pathogenic	Likely pathogenic	1	Chinese	4/106	Missense
c.6487C>T (p.Arg2163Cys)	Pathogenic	Likely pathogenic	1	Malay	39/106	Missense
c.7268T>A (p.Met2423Lys)	Pathogenic	Variant of uncertain significance	3	Indian	45/106	Missense
c.14111C>T (p.Thr4704Met)	Pathogenic	Likely pathogenic	1	Indian	96/106	Missense
c.742G>T (p.Gly248Trp)	Likely pathogenic	Likely pathogenic	1	Chinese	12/106	Missense
c.1186G>T (p.Glu396X)	NA*	Pathogenic	3	Malay	9/106	Stop gained
c.2654G>A (p.Arg885His)	Conflicting**	Likely pathogenic	3	Indian	21/106 (outside mutational hotspot)	Missense
c.8554C>T (p.Arg2852X)	Variant of uncertain significance	Likely pathogenic	1	Chinese	55/106 (outside mutational hotspot)	Stop gained

Both ClinVar and InterVar classifications are included in this table. (Orange: defined as pathogenic in this study; Blue: defined as likely pathogenic in this study)

*Not found in ClinVar

**Conflicting refers to when different submitters assign different clinical significance to a variant. This includes variants which have the following combination of classifications from different submitters:

1. (Pathogenic or Likely pathogenic or Benign or Likely benign) AND Uncertain significance
2. (Pathogenic or Likely pathogenic) AND (Benign or Likely benign)

Table 2: Diseases associated with pathogenic and likely pathogenic *RYR1* variants

Variant	Malignant hyperthermia susceptibility	Minicore myopathy with external ophthalmoplegia	Congenital myopathy with fibre type disproportion	Central core myopathy
c.325C>T (p.Arg109Trp)	-	Pathogenic	Likely pathogenic	-
c.6487C>T (p.Arg2163Cys)	Pathogenic	-	-	Pathogenic
c.7268T>A (p.Met2423Lys)	-	Pathogenic	Pathogenic	-
c.14111C>T (p.Thr4704Met)	Likely pathogenic/ Variant of uncertain significance**	Pathogenic	Likely pathogenic	Pathogenic
c.742G>T (p.Gly248Trp)	Likely pathogenic	-	-	-
c.1186G>T (p.Glu396X)*	-	-	-	-
c.2654G>A (p.Arg885His)	Variant of uncertain significance	Variant of uncertain significance	Variant of uncertain significance	-
c.8554C>T (p.Arg2852X)***	-	-	-	-

*Not found in ClinVar. Labelled as pathogenic in InterVar.

**Various submitters to ClinVar provided different clinical significance for this variant in relation to MH-susceptibility.

***Labelled as Variant of uncertain significance for RYR1-related disorders in ClinVar. Disorders were not specified.

“-”: No information regarding the clinical significance of the RYR1 variant in relation to this disease